Silo Pharma 2025 Q2 Earnings Narrowed Losses, Persistent Challenges

Silo Pharma (SILO) reported its fiscal 2025 Q2 earnings on Aug 13th, 2025, with mixed results. The company slightly improved its bottom-line losses but struggled to grow revenue.

Silo Pharma's total revenue held steady at $18,025 in Q2 2025, unchanged from the same period in 2024. The company's sole revenue stream came from license fee revenue, which accounted for the entire $18,025 in earnings.

The company narrowed its per-share loss to $0.19 in Q2 2025, an improvement of 38.7% compared to a $0.31 per share loss in the prior-year period. However, Silo Pharma's net loss expanded to $1.20 million, a 29.2% increase from the $931,779 loss in Q2 2024. The firm has now posted losses for five consecutive years in the same quarter, underscoring its ongoing financial struggles.

Despite the revenue stability and slight EPS improvement, the overall earnings picture remains bleak, with the company’s losses widening in absolute terms.

Following the earnings report, Silo Pharma's stock gained 3.91% in a single trading day, surged 17.13% for the week, and climbed 17.78% month-to-date.

The strategy of buying Silo Pharma shares following a quarter with stable or rising revenue and holding for 30 days has historically underperformed. Over the past three years, the approach delivered a total return of -88.93%, versus a 69.89% gain for the benchmark, for an excess return of -158.82%. The compound annual growth rate was -54.72%, and the Sharpe ratio of -0.37 highlights poor risk-adjusted returns. Notably, the maximum drawdown remained at 0.00%, suggesting the 30-day holding period limited exposure to additional downside risks.

Silo Pharma’s CEO acknowledged the company's challenges in a competitive pharmaceutical landscape, emphasizing innovation and operational efficiency as key drivers of future growth. He pointed to R&D advancements and strategic partnerships as tools to enhance long-term positioning. The CEO also highlighted the importance of cost control and market diversification, expressing confidence in the company’s ability to deliver sustainable profitability despite external pressures.

Looking ahead, Silo Pharma expects revenue to stabilize in the second half of 2025, with an estimated EPS range of $-0.15 to $-0.10 for the year. The company aims to reduce its net losses by 20% year-over-year through operational restructuring and R&D efficiency improvements. Capital expenditures are projected to remain conservative at $12 million, prioritizing high-impact initiatives. Management remains focused on long-term value creation, without disclosing specific short-term revenue targets.

Additional News
Recent developments in Nigeria include a federal government initiative to unlock $150 billion in dormant land capital to stimulate economic growth. The Ministry of Housing and Urban Development highlighted the move as a key step toward addressing infrastructure and development gaps. Meanwhile, Lagos State lawmakers introduced a new tenancy bill aimed at reducing estate agent fees to 5% to protect tenants from overcharging.

In another significant development, the Petroleum Technology Development Fund (PTDF) and the Nigerian National Petroleum Company Limited (NNPCL) signed a Memorandum of Understanding to boost innovation in both oil and renewable energy sectors. This collaboration is expected to enhance human capital development and technological advancement in Nigeria’s energy landscape.

Security concerns remain high as the Defence Headquarters denied reports of a bandit leader’s surrender. Additionally, a federal hospital in Oyo State was vandalized by unidentified individuals, raising alarms over public infrastructure safety.